• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炔烃作为潜伏弹头共价靶向 SARS-CoV-2 主要蛋白酶。

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.

机构信息

Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, California 90089, United States.

Molecular and Computational Biology, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States.

出版信息

J Med Chem. 2023 Sep 14;66(17):12237-12248. doi: 10.1021/acs.jmedchem.3c00810. Epub 2023 Aug 18.

DOI:10.1021/acs.jmedchem.3c00810
PMID:37595260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10510381/
Abstract

There is an urgent need for improved therapy to better control the ongoing COVID-19 pandemic. The main protease M plays a pivotal role in SARS-CoV-2 replications, thereby representing an attractive target for antiviral development. We seek to identify novel electrophilic warheads for efficient, covalent inhibition of M. By comparing the efficacy of a panel of warheads installed on a common scaffold against M, we discovered that the terminal alkyne could covalently modify M as a latent warhead. Our biochemical and X-ray structural analyses revealed the irreversible formation of the vinyl-sulfide linkage between the alkyne and the catalytic cysteine of M. Clickable probes based on the alkyne inhibitors were developed to measure target engagement, drug residence time, and off-target effects. The best alkyne-containing inhibitors potently inhibited SARS-CoV-2 infection in cell infection models. Our findings highlight great potentials of alkyne as a latent warhead to target cystine proteases in viruses and beyond.

摘要

目前迫切需要改进治疗方法,以更好地控制持续的 COVID-19 大流行。主蛋白酶 M 在 SARS-CoV-2 的复制中起着关键作用,因此成为抗病毒药物开发的一个有吸引力的靶点。我们试图寻找新型亲电弹头,以有效、共价抑制 M。通过比较一组安装在共同支架上的弹头对 M 的功效,我们发现末端炔烃可以作为潜伏弹头共价修饰 M。我们的生化和 X 射线结构分析揭示了炔烃和 M 的催化半胱氨酸之间形成不可逆的乙烯基-硫醚键。基于炔烃抑制剂的可点击探针被开发出来,用于测量靶标结合、药物停留时间和脱靶效应。最好的含炔烃抑制剂在细胞感染模型中强烈抑制 SARS-CoV-2 感染。我们的发现突出了炔烃作为潜伏弹头的巨大潜力,可以针对病毒和其他生物中的半胱氨酸蛋白酶。

相似文献

1
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.炔烃作为潜伏弹头共价靶向 SARS-CoV-2 主要蛋白酶。
J Med Chem. 2023 Sep 14;66(17):12237-12248. doi: 10.1021/acs.jmedchem.3c00810. Epub 2023 Aug 18.
2
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.探索多样化的反应弹头以设计 SARS-CoV-2 主蛋白酶抑制剂。
Eur J Med Chem. 2023 Nov 5;259:115667. doi: 10.1016/j.ejmech.2023.115667. Epub 2023 Jul 19.
3
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.含奈玛特韦的 SARS-CoV-2 主蛋白酶抑制剂的炔衍生物通过与亲核半胱氨酸发生共价反应来抑制。
J Med Chem. 2023 Feb 23;66(4):2663-2680. doi: 10.1021/acs.jmedchem.2c01627. Epub 2023 Feb 9.
4
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.SARS-CoV-2 主蛋白酶药物设计、检测方法开发及耐药性研究。
Acc Chem Res. 2023 Jan 17;56(2):157-168. doi: 10.1021/acs.accounts.2c00735. Epub 2022 Dec 29.
5
Pyrazolidinone-based peptidomimetic SARS-CoV-2 M inhibitors.基于吡唑烷酮的拟肽 SARS-CoV-2 M 抑制剂。
Bioorg Med Chem Lett. 2023 Nov 15;96:129530. doi: 10.1016/j.bmcl.2023.129530. Epub 2023 Oct 20.
6
Discovery of highly potent covalent SARS-CoV-2 3CL inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19.发现具有 2-磺酰基-1,3,4-噁二唑骨架的高效共价 SARS-CoV-2 3CL 抑制剂,用于抗击 COVID-19。
Eur J Med Chem. 2023 Nov 15;260:115721. doi: 10.1016/j.ejmech.2023.115721. Epub 2023 Aug 17.
7
Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome.快速有效地预测 SARS-CoV-2 主蛋白酶和 20S 蛋白酶体共价抑制剂的绝对结合自由能。
J Am Chem Soc. 2022 May 4;144(17):7568-7572. doi: 10.1021/jacs.2c00853. Epub 2022 Apr 18.
8
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.非肽类哌嗪衍生物作为共价 SARS-CoV-2 主蛋白酶抑制剂的发现和晶体学研究。
J Med Chem. 2022 Dec 22;65(24):16902-16917. doi: 10.1021/acs.jmedchem.2c01716. Epub 2022 Dec 7.
9
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease.一种与共价弹头结合的氮杂肽平台,用于发现针对新型冠状病毒主要蛋白酶的高效抑制剂。
bioRxiv. 2023 Apr 12:2023.04.11.536467. doi: 10.1101/2023.04.11.536467.
10
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.将严重急性呼吸综合征冠状病毒2(SARS-CoV-2)蛋白酶作为治疗2019冠状病毒病(COVID-19)的治疗策略所面临的挑战。
ACS Infect Dis. 2021 Jun 11;7(6):1457-1468. doi: 10.1021/acsinfecdis.0c00815. Epub 2021 Feb 11.

引用本文的文献

1
Mechanistic Insights into Nitrile and Alkyne Covalent Inhibitors of the SARS-CoV-2 Main Protease.对严重急性呼吸综合征冠状病毒2型主要蛋白酶的腈类和炔类共价抑制剂的作用机制见解
ACS Catal. 2025 Jan 17;15(2):1158-1169. doi: 10.1021/acscatal.4c06020. Epub 2025 Jan 5.
2
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M inhibitors with potent in vivo efficacy.基于结构发现具有高生物利用度、共价、广谱冠状病毒M抑制剂并具有强大的体内疗效。
Sci Adv. 2025 Apr 25;11(17):eadt7836. doi: 10.1126/sciadv.adt7836. Epub 2025 Apr 23.
3
Development of potential immunomodulatory ligands targeting natural killer T cells inspired by gut symbiont-derived glycolipids.

本文引用的文献

1
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.含奈玛特韦的 SARS-CoV-2 主蛋白酶抑制剂的炔衍生物通过与亲核半胱氨酸发生共价反应来抑制。
J Med Chem. 2023 Feb 23;66(4):2663-2680. doi: 10.1021/acs.jmedchem.2c01627. Epub 2023 Feb 9.
2
Dual Inhibitors of Main Protease (M) and Cathepsin L as Potent Antivirals against SARS-CoV2.双重主蛋白酶(M)和组织蛋白酶 L 抑制剂可有效对抗 SARS-CoV-2 病毒
J Am Chem Soc. 2022 Nov 23;144(46):21035-21045. doi: 10.1021/jacs.2c04626. Epub 2022 Nov 10.
3
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
受肠道共生菌衍生糖脂启发开发靶向自然杀伤T细胞的潜在免疫调节配体。
Commun Chem. 2025 Apr 1;8(1):98. doi: 10.1038/s42004-025-01497-z.
4
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.探索新型冠状病毒主要蛋白酶的共价抑制剂:从拟肽到新型骨架
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2460045. doi: 10.1080/14756366.2025.2460045. Epub 2025 Feb 6.
5
Identification of novel SARS-CoV-2 3CLpro inhibitors by molecular docking, assays, molecular dynamics simulations and DFT analyses.通过分子对接、实验、分子动力学模拟和密度泛函理论分析鉴定新型严重急性呼吸综合征冠状病毒2 3C样蛋白酶抑制剂
Front Pharmacol. 2024 Oct 30;15:1494953. doi: 10.3389/fphar.2024.1494953. eCollection 2024.
6
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads.酮缩醛化不饱和糖作为多功能靶向半胱氨酸的共价弹头的开发。
Commun Chem. 2024 Sep 9;7(1):201. doi: 10.1038/s42004-024-01279-z.
7
Recent Advances on Targeting Proteases for Antiviral Development.靶向蛋白酶用于抗病毒药物研发的最新进展
Viruses. 2024 Feb 27;16(3):366. doi: 10.3390/v16030366.
8
On the origins of SARS-CoV-2 main protease inhibitors.关于严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的起源
RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25.
9
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.新型冠状病毒主蛋白酶抑制剂的最新进展:从奈玛特韦到未来展望。
Biomolecules. 2023 Sep 2;13(9):1339. doi: 10.3390/biom13091339.
COVID-19 mRNA 疫苗在奥密克戎为主导期间对免疫功能低下成年人 COVID-19 相关住院的有效性- VISION 网络,10 个州,2021 年 12 月至 2022 年 8 月。
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4.
4
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.SARS-CoV-2 主蛋白酶结合位点的热点残基和耐药突变:设计、鉴定及与全球流行病毒基因组的相关性。
Biochem Biophys Res Commun. 2022 Nov 12;629:54-60. doi: 10.1016/j.bbrc.2022.09.010. Epub 2022 Sep 7.
5
Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity.新型冠状病毒肺炎疫苗的过敏反应和过敏:关于实现群体免疫的特征及潜在障碍的叙述性综述
Health Sci Rep. 2022 Aug 24;5(5):e787. doi: 10.1002/hsr2.787. eCollection 2022 Sep.
6
Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.在一组住院和非住院的COVID-19患者中,奈玛特韦/利托那韦医学禁忌的患病率。
Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.
7
Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2.通过I型干扰素和化学抑制剂抑制脂肪酸合酶作为一种针对严重急性呼吸综合征冠状病毒2的广谱抗病毒策略。
Acta Pharm Sin B. 2022 Apr;12(4):1624-1635. doi: 10.1016/j.apsb.2022.02.019. Epub 2022 Feb 28.
8
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.新冠疫苗在免疫功能低下患者中的有效性:系统评价和荟萃分析。
BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
9
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
10
Electrophilic warheads in covalent drug discovery: an overview.亲电弹头在共价药物发现中的应用:概述。
Expert Opin Drug Discov. 2022 Apr;17(4):413-422. doi: 10.1080/17460441.2022.2034783. Epub 2022 Feb 6.